2021 AABB Annual Meeting On-Demand

Oct 17, 2021 ‐ Oct 19, 2021


Access to the 2021 AABB Annual Meeting On-Demand sessions expires on December 31, 2023. Each session includes the on-demand recording and a downloadable MP3 audio file. Closed captioning in Spanish and English also available for most sessions. Some speaker handouts may be available, but in general, presentation handouts are not available/included.



Sessions

AM21-01: The Impact of the COVID-19 Pandemic on the Future Landscape of Education and Training in Transfusion Medicine

Oct 17, 2021 11:15am ‐ Oct 17, 2021 12:15pm

Credits: None available.

The COVID-19 pandemic changed nearly every aspect of our personal and professional lives, including education and training in transfusion medicine. We have implemented virtual learning and adapted in-person rotations to meet social distancing guidelines. As we look back on the adjustments made in the last year, we realize that the COVID-19 pandemic has already influenced the future landscape of education and training in transfusion medicine. In this session, we will share successful strategies utilized in both physician and technologist training programs. We will address the challenges faced and outcome data associated with these adaptations to traditional instruction. Finally, we will discuss which modifications have proven advantageous and which may outlive pandemic restrictions.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe strategies employed to continue to provide effective education and training in transfusion medicine during the COVID-19 pandemic.
  • List challenges associated with promoting successful learning in virtual and socially distanced settings.
  • Utilize outcome data to predict how the pandemic will shape education and training in transfusion medicine into the future.
Moderator(s): Speaker(s): Disclosures
  • Lynsi Rahorst, MHPE, MT(ASCP)SBB : Nothing to Disclose
  • Lorraine Blagg, MA, MLS(ASCP)SBB : Nothing to Disclose
  • Yulia Lin, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-02: Maintaining an Adequate Platelet and Plasma Supply Through a Multifaceted Approach to Avoid Critical Shortages

Oct 17, 2021 11:15am ‐ Oct 17, 2021 12:15pm

Credits: None available.

Decreasing platelet donors and increasing usage due to an aging population with losses due to new sampling requirements for bacteria detection may lead to shortages. Recent changes to deferral policies (e.g.,12 to 3 months) speak to the need to retain more donors. Pathogen reduction technologies (PRT) could allow further deferral relaxation (e.g., deferrals for men who have had sex with other men or travel to malaria endemic countries) and replacement of screening to increase platelet and plasma availability. To maintain blood supply continuity amid emergence of transfusion-transmitted diseases and in times of disaster, preparedness plans including rapid scalability of PRT for the platelet and plasma supply to allow for temporary deferral relaxation and increased production would be required. The session concludes considering PRT as part of business continuity plans of blood centers and hospitals to avoid critical shortages.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Evaluate why the current state of the platelet supply is at risk of critical shortages.
  • Apply a multifaceted approach, including changes and relaxation of some deferral policies with the use of PRT, building the flexibility needed during times of disaster to grow the donor pool and increase production of plasma and platelets.
  • Prepare business continuity plans for hospitals and blood centers in case an agent is transfusion-transmissible and using PRT to avoid critical shortages.
Speaker(s): Disclosures
  • Lauren Crowder, MPH, CPH : Nothing to Disclose
  • Suchitra Pandey, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-03: Challenges in Apheresis Cellular Collections during the COVID-19 Pandemic

Oct 17, 2021 11:15am ‐ Oct 17, 2021 12:15pm

Credits: None available.

The field of cellular therapy has become increasingly complicated in all aspects, including technical, patient, environment, and regulatory. For example, the logistics of apheresis collection as well as the utilization of fresh stem cell product have changed significantly during the current COVID-19 pandemic. In this session, different logistical solutions that apheresis collection facilities have used during the pandemic will be discussed. New regulatory requirements introduced during the COVID-19 pandemic will be reviewed (e.g new FDA guidance) and how these can be implemented into routine operations will be discussed.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Summarize different logistical modifications apheresis collection facilities adapted during the COVID-19 pandemic
  • Discuss different logistical modifications transplant centers have adapted during the COVID-19 pandemic
  • Review updated regulatory cellular therapy requirements during the COVID-19 pandemic and their effect on collection of cells for further manufacturing
Moderator(s): Speaker(s): Disclosures
  • Monika Paroder, MD, PhD : Nothing to Disclose
  • Huy Pham, MD, MPH : Consultant: Sanofi; Honoraria: Argenx; Royalty: Elsevier
  • Joseph Schwartz, MD, MPH : Consultant: Gamida Cell; Plass-Free, Argen X
Members: $20.00
Standard: $25.00

AM21-04: Wizardry School of Antigens and Antibodies

Oct 17, 2021 7:15pm ‐ Oct 17, 2021 8:15pm

Credits: None available.

AABB’s Wizardry School of Antigens and Antibodies is back for its sixth year classes. Medical Laboratory Scientists and physicians will be challenged to demonstrate their blood bank wizarding skills in interactive case studies in this series inspired by one of our favorite wizards. Students will be presented with pretransfusion/prenatal test scenarios to practice their antibody identification magic, receive problem solving approaches from Wizardry School house faculty, and learn serologic practices from fellow blood bank professionals as all witches and wizards are encouraged to share their spells and potions using interactive audience response. “Graduate” from the sixth school year with new and/or refreshed serological knowledge and a little muggle magic.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Discuss how others approach serological testing problems.
  • Utilize efficient and reliable processes for problem resolution.
  • Describe the latest information on serological testing.
Speaker(s): Disclosures
  • Jayanna Slayten, MS, MT(ASCP)SBB : Nothing to Disclose
  • Monica Kalvelage, MT(ASCP)MB,SBB : Nothing to Disclose
  • Susan Johnson, MSTM, MT(ASCP)SBB : Speaker's Bureau, Honoraria: Immucor, Grifols, Ortho; Book Royalties: AABB Press
  • Rebecca Coward, MT(ASCP)SBB : Honoraria, Speaker's Bureau: Immucor
Members: $20.00
Standard: $25.00

AM21-05: Cryoprecipitated Anti-Hemophiliac Factor: Challenges, Solutions and Innovation

Oct 17, 2021 2:30pm ‐ Oct 17, 2021 3:30pm

Credits: None available.

Cryoprecipitated anti-hemophiliac factor (Cryo) is transfused to patients for acquired hypofibrinogenemia, primarily due to blood loss. For the last several years, there has been a steadily increasing demand for Cryo. However, given the complexity and challenges of manufacturing Cryo, blood centers have been unable to keep up with increasing hospital demand. This supply-demand mismatch was acutely worsened due to COVID-19 related manufacturing disruptions, which has resulted in a critical shortage of the national Cryo inventory. Speakers will review current literature regarding fibrinogen replacement, and offer insights into usage trends that is driving the increased demand for Cryo. They will describe the current Cryo manufacturing challenges, especially focusing on the requirement to use FFP as the source material. This session will also dwell into solutions that the American Red Cross is considering, including consideration of manufacturing Cryo from PF24, rather than FFP.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe the reasons for increasing Cryo demand.
  • Review the challenges associated with manufacturing Cryo, including the impact of COVID-19 related disruptions to manufacturing.
  • Discuss the potential of using PF24 to manufacture Cryo.
Moderator(s): Speaker(s): Disclosures
  • Pampee Young, MD, PhD : Medical Advisory Board: Fresenius Kabi; Consultant: Roche, Ortho Diagnositcs
  • Parvez Lokhandwala, MD, PhD : Nothing to Disclose
  • Magali Fontaine, MD, PhD : Grant/Research Support: Cerus
Members: $20.00
Standard: $25.00

AM21-06: Oral Abstract Session -- Blood Donation

Oct 17, 2021 2:30pm ‐ Oct 17, 2021 3:30pm

Credits: None available.

Oral abstract session focused on blood donation.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify prediction models for hemoglobin deferral or low-iron donation to tailor inter-donation intervals to minimize donor risk and deferral for at risk donors
  • Evaluate the effectiveness of identifying and encouraging treatment of low iron states in donors through the use of prior and subsequent ferritin and hemoglobin testing, return rates and return donation intervals
  • Compare and contrast risk factors for HIV infection in blood donors during two time periods: 2015-2020 and 2010-2013
  • Review effectiveness of DHQ questions for ART, PrEP/PEP to estimate under-reporting of high-risk situations in donors
Moderator(s):
  • Eric Senaldi, MD, New York Blood Center
  • Dawn Ward, Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA
Speaker(s): Disclosures
  • Dawn Ward : Nothing to Disclose
  • Eric Senaldi, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-07: Coverage and Reimbursement Policy for Transfusion Medicine and Cell Therapy: What U.S. Hospitals Need to Know in 2021

Oct 17, 2021 2:30pm ‐ Oct 17, 2021 3:30pm

Credits: None available.

Transfusion physicians, technologists, managers, and support staff need to have at least a basic understanding billing and coding procedures. Those who are responsible for maintaining appropriate billing and coding need to keep up with the constantly changing expectations for coding and billing. This session is designed to provide a comprehensive review of current coding and reimbursement information, including critical updates, as well as share best practices from hospitals. AABB staff will also discuss Medicare advocacy and resources to help hospitals ensure they receive appropriate payment.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Describe the current status of Medicare coverage and reimbursement for Transfusion Medicine and Cellular Therapy.
  • Discuss AABB’s advocacy approach for expanded Medicare coverage and enhanced reimbursement.
  • List appropriate codes to use to ensure appropriate reimbursement.
  • Describe AABB resources that assist with transfusion medicine and cellular therapy billing and coding needs.
Moderator(s): Speaker(s):
  • Stephanie Pierce, MBA, MT(ASCP), Providence Health
  • Dr. Mary Berg, MD, Professor of Clinical Practice, Pathology Medical Director, Transfusion Services, University of Colorado
Disclosures
  • Susan Leppke, MPH : Nothing to Disclose
  • Stephanie Pierce, MBA, MT(ASCP) : Nothing to Disclose
  • Mary Berg, MD : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-08: Blood Bank and Transfusion Medicine Fundamentals I: Immunohematology Building Blocks

Oct 17, 2021 11:15am ‐ Oct 17, 2021 12:15pm

Credits: None available.

This is the kick off the Blood Bank Fundamentals Program with an introduction to certification, Immunohematology/Immunology and Lab Math.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Explain the American Society of Clinical Pathologist (ASCP) SBB and BB exam requirements
  • Review and explain the topics outlined on the ASCP BB/SBB Exam Content Outline
  • Define and relate pertinent information from the ASCP Content Outline that will be on these exams to aid in preparing for the BB or SBB exam.
  • Discover helpful hints for studying for and taking these exams.
  • Apply knowledge for interactive question and answer polling session.
Moderator & Speaker(s): Speaker(s): Disclosures
  • Jayanna Slayten, MS, MT(ASCP)SBB : Nothing to Disclose
  • Kathy Haddaway, MLS(ASCP), SBB(ASCP) : Nothing to Disclose
  • LeeAnn Walker, MEd, MT(ASCP)SBB : Nothing to Disclose
  • Diana Riddle, MLS(ASCP)SBB : Nothing to Disclose
Members: $20.00
Standard: $25.00

AM21-09: Transfusion Medicine Access in Resource-Constrained Areas

Oct 17, 2021 3:45pm ‐ Oct 17, 2021 4:45pm

Credits: None available.

The need to produce more with less is an ongoing reality in many sectors, including health care. Like developing countries, there are many resource-constrained states in the US where this reality imposes a further burden on the health care system. A state's poverty level results in increased comorbidity rates in rural populations such as cardiovascular disease and obesity. Furthermore, rural residents face significant barriers to health care access, including transfusion medicine services. In addition, rural areas are not staffed with research capabilities or staff routinely engaged in clinical research, making products that require IND and/or IRB-supported processes unfamiliar and less accessible. We will review access challenges to providing transfusion medicine services and products in resource-poor states through this presentation. Using examples and data from the recent COVID-19 pandemic, how the challenges to access TM services and products were overcome will be demonstrated.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.



Learning Objectives:
  • Review transfusion medicine services access challenges in resource-constrained areas.
  • Describe challenges posed by the COVID -19 pandemic by providing data on utilization of convalescent plasma based on attributes such as rural vs. urban, teaching hospital designation, and hospital size/complexity (availability of tertiary care services).
  • Demonstrate how challenges to access in transfusion medicine can be overcome through concepts such as allocative efficiency.
Speaker(s):
  • Dr. Pampee P. Young, MD, PhD, Chief Medical Officer, Biomedical Services, American Red Cross
  • Dr. Tina Ipe, MD, MPH, Division Director of Transfusion Medicine Services, Department of Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences
Disclosures
  • Pampee Young, MD, PhD : Medical Advisory Board: Fresenius Kabi; Consultant: Roche, Ortho Diagnositcs
  • Tina Ipe, MD, MPH : Consultant, Grant/Research Support: Terumo Blood and Cell Technology; Speaker's Bureau: Alexion Inc.
Members: $20.00
Standard: $25.00

AM21-10: Exploring Atypical and Complex Transfusion Reactions: Learning through Case Studies

Oct 17, 2021 3:45pm ‐ Oct 17, 2021 4:45pm

Credits: None available.

This session will focus on atypical, complex and combination transfusion reactions including patients presenting with unusual symptoms, with a history of complex underlying illness and with delayed onset of symptoms. Using archived case materials from multiple institutions, the attendees will be presented cases fully investigated by the Blood Bank and further enhanced by an indepth review of the patients electronic medical record. Case studies will be presented using a structured format allowing for attendee participation in determining adverse reaction category, imputability and severity of the reaction as per CDC NHSN Biovigilance Component Hemovigilance Module Surveillance Protocol.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Recognize and discuss the Blood Bank role in the work-up of complex transfusion reactions.
  • Describe the steps in management and prevention of transfusion reactions.
  • Define and classify atypical and combination reactions according to the CDC’s National Healthcare Safety Network Hemovigilance Module Surveillance Protocol.
Speaker(s): Disclosures
  • Sajjad Hassan, MD : Nothing to Disclose
  • David Unold : Nothing to Disclose
Members: $20.00
Standard: $25.00